The cholesterol ester transfer protein inhibitor, anacetrapib (vol 22, pg 245, 2011)

被引：0
|
作者：
Jialal, I
Kaur, J.
机构：
来源：
CURRENT OPINION IN LIPIDOLOGY | 2011年 / 22卷 / 04期
关键词：
D O I：
10.1097/MOL.0b013e328348b6e5
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：326 / 326
页数：1
相关论文
共 50 条
  • [41] A role of phospholipid transfer protein and cholesteryl ester transfer protein in cholesterol efflux
    Tchoua, U
    Escher, G
    Maugeais, C
    Sviridov, D
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : E91 - E91
  • [42] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Hanjing Chen
    Weili Chen
    Hui Li
    Hongrong Xu
    Fei Yuan
    Lei Sheng
    Chao Liu
    Pingping Lin
    Mengjie Yang
    Xuening Li
    Yang Liu
    Brittany Marie Walker
    Ferdous Gheyas
    Marian Iwamoto
    S. Aubrey Stoch
    Rajesh Krishna
    Advances in Therapy, 2021, 38 : 3973 - 3985
  • [43] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Chen, Hanjing
    Chen, Weili
    Li, Hui
    Xu, Hongrong
    Yuan, Fei
    Sheng, Lei
    Liu, Chao
    Lin, Pingping
    Yang, Mengjie
    Li, Xuening
    Liu, Yang
    Walker, Brittany Marie
    Gheyas, Ferdous
    Iwamoto, Marian
    Stoch, S. Aubrey
    Krishna, Rajesh
    ADVANCES IN THERAPY, 2021, 38 (07) : 3973 - 3985
  • [44] Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers
    Krishna, Rajesh
    Bergman, Arthur J.
    Jin, Bo
    Garg, Amit
    Roadcap, Brad
    Chiou, Rita
    Dru, James
    Cote, Josee
    Laethem, Tine
    Wang, Regina W.
    Didolkar, Varsha
    Vets, Eva
    Gottesdiener, Keith
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (01): : 80 - 87
  • [45] Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
    Gotto, Antonio M., Jr.
    Cannon, Christopher P.
    Shah, Sukrut
    Liu, Sherry
    Li, Susie
    Stepanavage, Michael
    Brinton, Eliot
    Davidson, Michael
    Dansky, Hayes
    Mitchel, Yale
    Barter, Philip
    CIRCULATION, 2011, 124 (21)
  • [46] Cholesterol ester transfer protein: A molecule with three faces?
    Stevenson, CG
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1998, 35 (06) : 517 - 546
  • [47] Cholesterol ester transfer protein in children on peritoneal dialysis
    Tanaka, Y
    Matsuyama, T
    Ishikura, K
    Hataya, H
    Ikeda, M
    Honda, M
    PERITONEAL DIALYSIS INTERNATIONAL, 2004, 24 (03): : 281 - 286
  • [48] New Horizons for Cholesterol Ester Transfer Protein Inhibitors
    Schwartz, Gregory G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2012, 14 (01) : 41 - 48
  • [49] Exploration of aminoheterocycles as cholesterol ester transfer protein inhibitors
    Wang, Yufeng
    Yang, Wu
    Finlay, Heather
    Jiang, Ji
    Harikrishnan, Lalgudi
    Kamau, Muthoni
    Van Kirk, Katy
    Nirschl, David
    Taylor, David S.
    Chen, Alice Ye A.
    Yin, Xiaohong
    Sleph, Paul
    Yang, Richard
    Adam, Leonard P.
    Salvati, Mark E.
    Wexler, Ruth R.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [50] Cholesterol ester transfer protein inhibition - Help or hindrance?
    Holt, Richard I. G.
    DIABETES OBESITY & METABOLISM, 2007, 9 (03): : 444 - 444
12345